NervGen Pharma Corp. 近日宣布,已成功完成针对其候选药物Nvg-291用于治疗慢性四肢瘫痪的三期注册研究"Restore"的二期临床试验结束会议。此次会议取得了积极成果,公司与美国食品药品监督管理局(FDA)就三期研究的整体开发计划达成了一致。
NervGen Pharma Corp. 近日宣布,已成功完成针对其候选药物Nvg-291用于治疗慢性四肢瘫痪的三期注册研究"Restore"的二期临床试验结束会议。此次会议取得了积极成果,公司与美国食品药品监督管理局(FDA)就三期研究的整体开发计划达成了一致。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.